Skip to main content
SpringerLink
Log in

Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

The resources devoted to managing metastatic prostate cancer are enormous, yet little attention has been given to directly measuring the economic consequences of treatment alternatives. The purpose of this article was to evaluate the pharmacoeconomics of available treatments for metastatic prostate cancer, including hormone-sensitive disease, androgen-independent prostate cancer and locally advanced/progressive disease. We identified 58 articles addressing economic issues related to metastatic prostate cancer.

Treatment alternatives with considerably different costs are available in many areas of disease management, most notably, medical androgen deprivation therapy (ADT) versus surgical castration; combined androgen blockage (CAB) versus monotherapy for initial treatment of hormone-sensitive disease; as well as bisphosphonates and bone-targeted radioisotopes for palliation. The few available pharmacoeconomic studies indicate that the additional costs are not supported by clear and compelling evidence of differences in survival or quality-of-life (QOL) outcomes. Our review revealed that authors often use considerably different assumptions about efficacy and survival outcomes in their analyses, which may be due to the inconsistency of available clinical evidence.

Although there have been many clinical trials comparing various therapies, we identified only three trials that included economic assessments. Thus, few sources of economic data are available and most pharmacoeconomic studies rely on information mined from indirect sources. We note that, while there has been considerable enthusiasm about the role of docetaxel regimens in the past 2 years, no study has yet examined the costs of these therapies.

Survival remains poor for metastatic disease, thus QOL is the primary consideration for many therapies. However, QOL for treatment of metastatic disease is poorly measured and, in most analyses, the impact of therapy on QOL was inferred based on speculation by the authors. Given the large cost burdens of these treatments, it is essential that we more fully understand the true QOL gains potentially offered by more expensive therapies.

The economic studies of advanced prostate cancer highlight several aspects of clinical care that are filled with considerable uncertainty and remain guided by forces other than optimal resource allocation. It is essential that we address the weaknesses in our understanding of the economic consequences of therapies for prostate cancer, and find ways to include economic information into the process of determining optimal therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56 (2): 106–130

    Article  PubMed  Google Scholar 

  2. Penson DF, Chan JM. Prostate cancer. In: Litwin MS, Saigal CS, editors. Urologic diseases in America. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 2007; NIH Publication No. 07-5512: 71–122

    Google Scholar 

  3. American Cancer Society. Cancer facts and figures 2007. Atlanta (GA): American Cancer Society, 2007

    Google Scholar 

  4. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293 (17): 2095–2101

    Article  PubMed  CAS  Google Scholar 

  5. Khan MA, Partin AW, Mangold LA, et al. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology 2003; 62 (5): 866–871

    Article  PubMed  Google Scholar 

  6. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941 (1): 293–297

    CAS  Google Scholar 

  7. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002; 168 (1): 9–12

    Article  PubMed  Google Scholar 

  8. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294 (2): 238–244

    Article  PubMed  CAS  Google Scholar 

  9. Loblaw D, Mendelson D, Talcott J, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Onc 2004; 22 (14): 2927–2941

    Article  Google Scholar 

  10. Seidenfeld J, Samson DJ, Aronson N, et al. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ) 1999 (4): i–x, 1–246, I1–I36, passim

    Google Scholar 

  11. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20 (19): 3972–3982

    Article  PubMed  Google Scholar 

  12. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14 (6): 1756–164

    PubMed  CAS  Google Scholar 

  13. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502–1512

    Article  PubMed  CAS  Google Scholar 

  14. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351 (15): 1513–1520

    Article  PubMed  CAS  Google Scholar 

  15. Armstrong AJ, Carducci MA. New drugs in prostate cancer. Curr Opin Urol 2006; 16 (3): 138–145

    Article  PubMed  Google Scholar 

  16. Brown ML, Riley GF, Schussler N, et al. Estimating health care costs related to cancer treatment from SEER: Medicare data. Med Care 2002; 40 (8 Suppl.): 104–117

    Google Scholar 

  17. Turini M, Redaelli A, Gramegna P, et al. Quality of life and economic considerations in the management of prostate cancer. Pharmacoeconomics 2003; 21 (8): 527–541

    Article  PubMed  Google Scholar 

  18. Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995; 87 (6): 417–426

    Article  PubMed  CAS  Google Scholar 

  19. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360 (9327): 103–106

    Article  PubMed  CAS  Google Scholar 

  20. Medical Research Council. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997; 79 (2): 235–246

    Article  Google Scholar 

  21. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with nodepositive prostate cancer. N Engl J Med 1999; 341 (24): 1781–1788

    Article  PubMed  CAS  Google Scholar 

  22. Krahn M, Ritvo P, Irvine J, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care 2003; 41 (1): 153–164

    Article  PubMed  Google Scholar 

  23. Kramer KM, Bennett CL, Pickard AS, et al. Patient preferences in prostate cancer: a clinician’s guide to understanding health utilities. Clin Prostate Cancer 2005; 4 (1): 15–23

    Article  PubMed  Google Scholar 

  24. Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol 2003; 56 (4): 317–325

    Article  PubMed  Google Scholar 

  25. Clark JA, Wray N, Brody B, et al. Dimensions of quality of life expressed by men treated for metastatic prostate cancer. Soc Sci Med 1997; 45 (8): 1299–1309

    Article  PubMed  CAS  Google Scholar 

  26. Sanford EJ, Paulson DF, Rohner TJ Jr, et al. The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma. J Urol 1977; 118 (6): 1019–1021

    PubMed  CAS  Google Scholar 

  27. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132 (7): 566–577

    PubMed  CAS  Google Scholar 

  28. Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95 (2): 361–376

    Article  PubMed  CAS  Google Scholar 

  29. Schellhammer PF. Combined androgen blockade for the treatment of metastatic cancer of the prostate. Urology 1996; 47 (5): 622–628

    Article  PubMed  CAS  Google Scholar 

  30. Dole EJ, Holdsworth MT. Nilutamide: an antiandrogen for the treatment of prostate cancer. Ann Pharmacother 1997; 31 (1): 65–75

    PubMed  CAS  Google Scholar 

  31. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321 (7): 419–424

    Article  PubMed  CAS  Google Scholar 

  32. Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998; 33 (2): 144–151

    Article  PubMed  CAS  Google Scholar 

  33. Dijkman GA, Janknegt RA, De Reijke TM, et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol 1997; 158 (1): 160–163

    Article  PubMed  CAS  Google Scholar 

  34. Janknegt RA, Abbou CC, Bartoletti R, et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993; 149 (1): 77–82; discussion 83

    PubMed  CAS  Google Scholar 

  35. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339 (15): 1036–1042

    Article  PubMed  CAS  Google Scholar 

  36. Iversen P, Rasmussen F, Klarskov P, et al. Long-term results of Danish Prostatic Cancer Group trial 86: goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer. Cancer 1993; 72 (12 Suppl.): 3851–3854

    Article  PubMed  CAS  Google Scholar 

  37. Tyrrell CJ, Altwein JE, Klippel F, et al. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer: the International Prostate Cancer Study Group. J Urol 1991; 146 (5): 1321–1326

    PubMed  CAS  Google Scholar 

  38. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355 (9214): 1491–1498

    Article  Google Scholar 

  39. Cox MC, Dahut WL, Figg WD. The use of thalidomide in androgen-independent prostate cancer. Urol Oncol 2006; 24 (3): 246–249

    Article  PubMed  CAS  Google Scholar 

  40. Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy: part II. Treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol 2005; 15 (3): 187–195

    Article  PubMed  Google Scholar 

  41. Goodin S, Medina P, Capanna T, et al. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. J Clin Oncol 2005; 23 (15): 3352–3357

    Article  PubMed  CAS  Google Scholar 

  42. Measuring Worth.Com. Five ways to compute the relative value of a US dollar amount, 1790–2005 [online]. Available from URL: http://www.measuringworth.com/calculators/compare/#; [Accessed 2007 Mar 20]

  43. Economic History Services. What was the exchange rate then? [online]. Available from URL: http://eh.net/hmit/exchange rates/ [Accessed 2007 Mar 20]

  44. Shahinian VB, Kuo YF, Freeman JL, et al. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst 2006; 98 (12): 839–845

    Article  PubMed  Google Scholar 

  45. Bonzani RA, Stricker HJ, Peabody JO, et al. Cost comparison of orchiectomy and leuprolide in metastatic prostate cancer. J Urol 1998; 160 (6 Pt 2): 2446–2449

    Article  PubMed  CAS  Google Scholar 

  46. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000; 92 (21): 1731–1739

    Article  PubMed  CAS  Google Scholar 

  47. Hillner BE, McLeod DG, Crawford ED, et al. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology 1995; 45 (4): 633–640

    Article  PubMed  CAS  Google Scholar 

  48. Nicol DL, Heathcote PS, Kateley GD, et al. Advanced prostate cancer: the role of high priced hormone therapy. Med J Aust 1993; 159 (1): 16–19

    PubMed  CAS  Google Scholar 

  49. Bennett CL, Matchar D, McCrory D, et al. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer 1996; 77 (9): 1854–1861

    Article  PubMed  CAS  Google Scholar 

  50. Penson DF, Ramsey S, Veenstra D, et al. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. J Urol 2005; 174 (2): 547–552; discussion 552

    Article  PubMed  Google Scholar 

  51. Ramsey S, Veenstra D, Clarke L, et al. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? Urology 2005; 66 (4): 835–839

    Article  PubMed  Google Scholar 

  52. Beemsterboer PM, de Koning HJ, Birnie E, et al. Advanced prostate cancer: course, care, and cost implications. Prostate 1999; 40 (2): 97–104

    Article  PubMed  CAS  Google Scholar 

  53. Henriksson P, Stege R. Cost comparison of parenteral estrogen and conventional hormonal treatment in patients with prostatic cancer. Int J Technol Assess Health Care 1991; 7 (2): 220–225

    Article  PubMed  CAS  Google Scholar 

  54. Nygard R, Norum J, Due J. Goserelin (zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis. Anticancer Res 2001; 21 (1B): 781–788

    PubMed  CAS  Google Scholar 

  55. Lucas MD, Strijdom SC, Berk M, et al. Quality of life, sexual functioning and sex role identity after surgical orchidectomy in patients with prostatic cancer. Scand J Urol Nephrol 1995; 29 (4): 497–500

    Article  PubMed  CAS  Google Scholar 

  56. Incrocci L, Hop WC, Wijnmaalen A, et al. Treatment outcome, body image, and sexual functioning after orchiectomy and radiotherapy for stage I–II testicular seminoma. Int J Radiat Oncol Biol Phys 2002; 53 (5): 1165–1173

    Article  PubMed  Google Scholar 

  57. Williams G, Lindsay S, Bowsher WG. Randomised crossover trial to assess the tolerability of LHRH analogue administration. Prostate Cancer Prostatic Dis 2003; 6 (2): 187–189

    Article  PubMed  CAS  Google Scholar 

  58. Byar D, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urologic Research Group Studies. National Cancer Institute Monograph 1988; 7: 165

    Google Scholar 

  59. Ockrim JL, Lalani EN, Laniado ME, et al. Transdermal estradiol therapy for advanced prostate cancer: forward to the past? J Urol 2003; 169 (5): 1735–1737

    Article  PubMed  CAS  Google Scholar 

  60. Drugstore.Com. Lupron depot [online]. Available from URL: http://www.drugstore.com/pharmacy/prices/drug-price.asp?ndc=00300334601&trx=175006 [Accessed 2007 Mar 19]

  61. Doctors Foster and Smith™. Diethylstilbestrol (DES) capsules (generic) [online]. Available from URL: http://www.drsfoster-smith.com/product/prod_display.cfm?siteid=0&pca-tid=11857&rxpid=27903_90 [Accessed 2007 Mar 15]

  62. Drugstore.Com. Casodex [online]. Available from URL: http://www.drugstore.com/pharmacy/prices/drugprice.asp?ndc=00310070530&trx=175006 [Accessed 2007 Mar 20]

  63. Chang SS, Benson MC, Campbell SC, et al. Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma. Cancer 2005; 103 (1): 11–21

    Article  PubMed  Google Scholar 

  64. Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 2005; 23 (32): 8247–8252

    Article  PubMed  CAS  Google Scholar 

  65. Sze WM, Shelley MD, Held I, et al. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy. A systematic review of randomised trials. Clin Oncol (R Coll Radiol) 2003; 15 (6): 345–352

    Article  CAS  Google Scholar 

  66. Malmberg I, Persson U, Ask A, et al. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy. Urology 1997; 50 (5): 747–753

    Article  PubMed  CAS  Google Scholar 

  67. McEwan AJ, Amyotte GA, McGowan DG, et al. A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone. Eur Urol 1994; 26 Suppl. 1: 26–31

    PubMed  Google Scholar 

  68. Shah Syed GM, Maken RN, Muzzaffar N, et al. Effective and economical option for pain palliation in prostate cancer with skeletal metastases: 32P therapy revisited. Nucl Med Commun 1999; 20 (8): 697–702

    Article  PubMed  Google Scholar 

  69. Oosterhof GO, Roberts JT, de Reijke TM, et al. Strontium (89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003; 44 (5): 519–526

    Article  PubMed  CAS  Google Scholar 

  70. Roque M, Martinez MJ, Alonso P, et al. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev 2003 (4): CD003347

    Google Scholar 

  71. Konski A. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60 (5): 1373–1378

    Article  PubMed  Google Scholar 

  72. Bloomfield DJ, Krahn MD, Neogi T, et al. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol 1998; 16 (6): 2272–2279

    PubMed  CAS  Google Scholar 

  73. Reed SD, Radeva JI, Glendenning GA, et al. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol 2004; 171 (4): 1537–1542

    Article  PubMed  Google Scholar 

  74. Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am 2004; 31 (2): 331–352

    Article  PubMed  Google Scholar 

  75. Botteman M, Barghout V, Stephens J, et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006; 17 (7): 1072–1082

    Article  PubMed  CAS  Google Scholar 

  76. National Institute for Health and Clinical Excellence. Prostate cancer (hormone-refractory): docetaxel. Analysis of cost impact. London: National Institute for Health and Clinical Excellence, 2006

    Google Scholar 

  77. Nair B, Wilt T, MacDonald R, et al. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 2002 (1): CD003506

  78. Konski A, Sherman E, Krahn M, et al. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). Int J Radiat Oncol Biol Phys 2005; 63 (3): 788–794

    Article  PubMed  CAS  Google Scholar 

  79. Konski A, Watkins-Bruner D, Brereton H, et al. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma. Cancer 2006; 106 (1): 51–57

    Article  PubMed  Google Scholar 

  80. Samant RS, Dunscombe PB, Roberts GH. A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer. Urol Oncol 2003; 21 (3): 171–177

    Article  PubMed  CAS  Google Scholar 

  81. Neymark N, Adriaenssen I, Gorlia T, et al. Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis. Eur J Cancer 2001; 37 (14): 1768–1774

    Article  PubMed  CAS  Google Scholar 

  82. Neymark N, Adriaenssen I, Gorlia T, et al. Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ 2002; 11 (3): 233–248

    Article  PubMed  CAS  Google Scholar 

  83. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337 (5): 295–300

    Article  PubMed  CAS  Google Scholar 

  84. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997; 15 (3): 1013–1021

    PubMed  CAS  Google Scholar 

  85. Pilepich MV. Phase III trial of androgen suppression adjuvant to definitive radiotherapy: long-term results of RTOG study 85-31. American Society of Clinical Oncology; 2003 May 31–Jun 3; Chicago

    Google Scholar 

  86. D’Amico AV, Manola J, Loffredo M, et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292 (7): 821–827

    Article  PubMed  Google Scholar 

  87. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6 (11): 841–850

    Article  PubMed  CAS  Google Scholar 

  88. Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 2004; 171 (4): 1393–1401

    Article  PubMed  Google Scholar 

  89. Zeliadt SB, Potosky AL, Etzioni R, et al. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology 2004; 64 (6): 1171–1176

    Article  PubMed  Google Scholar 

  90. Lyne JC. Medicare reform and your practice: what you need to know. Urology 2004; 64 (5 Suppl. 1): 2–7; discussion 15–18

    Article  PubMed  Google Scholar 

  91. Hillner BE, Roberts JD. Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer. J Natl Cancer Inst 2000; 92 (21): 1704–1706

    Article  PubMed  CAS  Google Scholar 

  92. Moinpour CM, Savage MJ, Troxel A, et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 1998; 90 (20): 1537–1544

    Article  PubMed  CAS  Google Scholar 

  93. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85 (5): 365–376

    Article  PubMed  CAS  Google Scholar 

  94. Ramsey SD, Zeliadt SB, Hall IJ, et al. On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer. Cancer 2007. In press

  95. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30 (6): 473–483

    Article  PubMed  Google Scholar 

  96. Feeny DH. The roles for preference-based measures in support of cancer research and policy. In: Lipscomb J, Gotay C, Snyder C, editors. Outcomes assessment in cancer: measures, methods, and applications. Cambridge: Cambridge University Press, 2005

    Google Scholar 

  97. Kind P. The EuroQol instrument: an index of health related quality of life. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven Press, 1996

    Google Scholar 

  98. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35 (11): 1095–1108

    Article  PubMed  CAS  Google Scholar 

  99. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24 (27): 4448–4456

    Article  PubMed  CAS  Google Scholar 

  100. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001; 58 (2 Suppl. 1): 10–17

    Article  Google Scholar 

Download references

Acknowledgements

The authors have no conflicts of interest related to the content of this review. No sources of funding were used in the preparation of this paper.

Author information

Authors and Affiliations

  1. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

    Steven B. Zeliadt &  David F. Penson

  2. Departments of Urology and Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA

    David F. Penson

Authors
  1. Steven B. Zeliadt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David F. Penson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David F. Penson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zeliadt, S.B., Penson, D.F. Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer. Pharmacoeconomics 25, 309–327 (2007). https://doi.org/10.2165/00019053-200725040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200725040-00004

Keywords

Search

Navigation